Top

World Journal of Surgery

Published in:

Open Access 01-02-2018 | Original Scientific Report

Preoperative ⁶⁸Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions

Authors: Olov Norlén, Harald Montan, Per Hellman, Peter Stålberg, Anders Sundin

Published in: World Journal of Surgery | Issue 2/2018

Abstract

Background

Small intestinal neuroendocrine tumors (SI-NETs) are the most common form of neoplasm in the small bowel. Radiological identification of primary tumors (PT), which may be multiple, is difficult, and therefore palpation of the entire small bowel is routinely performed during laparotomy. The aim was to determine detection rates of PT and peritoneal carcinomatosis (PC) with ⁶⁸Ga-DOTATOC/TATE-PET/CT in comparison with i.v. contrast-enhanced computed tomography (CE-CT) and thus to clarify whether modern functional imaging can mitigate the need for palpation of bowel during surgery enabling oncologically adequate laparoscopic resection.

Methods

A total of 28 patients with SI-NET who preoperatively underwent both ⁶⁸Ga-DOTATOC/TATE-PET/CT and CE-CT were included. The detection rates of PT and PC for PET/CT and CE-CT were compared to the findings in the surgical and histopathological reports. Appropriate statistical tests were used, and significance was set to p < 0.05.

Results

Out of 82 PT, 43 PT were not detected by any imaging modality. More PT lesions were detected with PET/CT (n = 39 [47.5%]) than with CE-CT (n = 10 [12.2%], p < 0.001). Also, PET/CT identified significantly more PC lesions than CE-CT (78 and 38%, p = 0.004, respectively).

Conclusion

PET/CT detected more PT and PC lesions than CE-CT. Some PTs and PC lesions were only detected by one of the modalities, and CT performed in conjunction with PET/CT should therefore be performed as a fully diagnostic CE-CT for optimal results. Palpation of the small bowel remains crucial during surgery in these patients because several PTs escaped detection by both PET/CT and CE-CT.

Rindi G, Klöppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401CrossRefPubMedPubMedCentral

Niederle MB, Hackl M, Kaserer K et al (2010) Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17:909–918CrossRefPubMed

Rindi G, Wiedenmann B (2011) Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 8:54–64CrossRefPubMed

Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712CrossRefPubMed

Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRefPubMed

Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72CrossRefPubMed

Klöppel G (2007) Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol 18:141–144CrossRefPubMed

Klöppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(S1):S1–S16CrossRefPubMed

Anlauf M (2011) Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification. Horm Metab Res 43:825–831CrossRefPubMed

10.

Öberg K, Castellano D (2011) Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 30(S1):3–7CrossRefPubMed

11.

Mocellin S, Nitti D (2013) Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 24:3040–3044CrossRefPubMed

12.

Sundin A, Arnold R, Baudin E et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology 105:212–244CrossRefPubMed

13.

Norlén O, Hessman O, Stålberg P et al (2010) Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg 34:1361–1367. https://doi.org/10.1007/s00268-010-0428-1 CrossRefPubMed

14.

Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663CrossRefPubMed

15.

Norlén O, Stålberg P, Zedenius J et al (2013) Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. Br J Surg 100:1505–1514CrossRefPubMed

16.

Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135CrossRefPubMed

17.

Sundin A, Arnold R, Baudin E et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology 105:212–244CrossRefPubMed

18.

van Essen M, Sundin A, Krenning EP et al (2013) Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol 10:102–114CrossRefPubMed

19.

Gilly FN, Cotte E, Brigand C et al (2006) Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol EJSO 32:597–601CrossRefPubMed

20.

Kianmanesh R, Ruszniewski P, Rindi G et al (2010) ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology 91:333–340CrossRefPubMed

21.

de Mestier L, Lardière-Deguelte S, Brixi H et al (2015) Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors. Neuroendocrinology 101:105–111CrossRefPubMed

22.

Pavel M, Baudin E, Couvelard A et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176CrossRefPubMed

23.

Norlén O, Stålberg P, Öberg K et al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36:1419–1431. https://doi.org/10.1007/s00268-011-1296-z CrossRefPubMed

24.

Dromain C, de Baere T, Lumbroso J et al (2005) Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23:70–78CrossRefPubMed

25.

Rivard JD, Temple WJ, McConnell YJ et al (2014) Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis. Am J Surg 207:760–765CrossRefPubMed

26.

Gabriel M, Decristoforo C, Kendler D et al (2007) ⁶⁸Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508–518CrossRefPubMed

27.

Flechsig P, Zechmann CM, Schreiweis J et al (2015) Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to ⁶⁸Ga-DOTATOC PET. Eur J Radiol 84:1593–1600CrossRefPubMed

28.

Schreiter NF, Nogami M, Steffen I et al (2012) Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol 22:458–467CrossRefPubMed

29.

Giesel FL, Kratochwil C, Mehndiratta A et al (2012) Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur J Radiol 81:2820–2825CrossRefPubMed

30.

Ambrosini V, Campana D, Bodei L et al (2010) ⁶⁸Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 51:669–673CrossRefPubMed

31.

Velikyan I, Sundin A, Sörensen J et al (2014) Quantitative and qualitative intrapatient comparison of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med 55:204–210CrossRefPubMed

32.

Poeppel TD, Binse I, Petersenn S et al (2013) Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Recent Res Cancer Res 194:353–371CrossRef

33.

Norlén O, Edfeldt K, Akerstrom G et al (2014) Peritoneal carcinomatosis from small intestinal neuroendocrine tumors: clinical course and genetic profiling. Surgery 156:1512–1521CrossRefPubMed

Title: Preoperative 68Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions
Authors: Olov Norlén
Harald Montan
Per Hellman
Peter Stålberg
Anders Sundin
Publication date: 01-02-2018
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 2/2018
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-017-4364-1

ACC 2024 Congress

Springer Medicine

Preoperative ⁶⁸Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

Development of Severe Hyperparathyroidism Despite Short-Term Renal Replacement Therapy

Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936–2015)

Hypoxia Increases Thyroid Cancer Stem Cell-Enriched Side Population

Retropharyngeal Parathyroid Glands: Important Differences

It’s Complicated: How Often are Patients with Primary Aldosteronism Cured After Adrenalectomy?

Lymph Node Evaluation in Robot-Assisted Versus Video-Assisted Thoracoscopic Esophagectomy for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis